Galderma Granted FDA Approval for New Therapeutic
Galderma just announced the FDA approved Nemolizumab (Nemluvio), a subcutaneous injection for treating prurigo nodularis in adults. Prurigo nodularis is a chronic skin condition marked by severe itching, painful nodules, and disrupted sleep, affecting large areas of the body. Nemolizumab targets chronic itch and inflammation by inhibiting IL-31 cytokine signaling. Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31.
Galderma Granted FDA Approval for New Therapeutic